REMS Programs: What You Need to Know About FDA Risk Evaluation and Mitigation Strategies

REMS Prescription Delay Estimator

REMS (Risk Evaluation and Mitigation Strategies) programs help ensure safe use of high-risk medications, but they often add delays to prescription processing. Based on FDA data showing average delays of 5.4 days for REMS drugs, this tool estimates how long it might take for your specific case.

Estimated Prescription Delay

0 days

This is an estimate based on FDA data showing that REMS drugs take an average of 5.4 days longer to be prescribed. Actual time may vary based on your specific circumstances.

When a drug can save your life but also carry a serious risk-like causing birth defects, sudden heart problems, or dangerous drops in white blood cells-the FDA doesn’t just slap on a warning label and call it a day. That’s where REMS programs come in. These aren’t just extra warnings. They’re structured, legally required systems designed to make sure high-risk medications are used safely, even when the benefits outweigh the dangers. If you’ve ever waited extra days to get a prescription filled, been asked to sign forms you didn’t understand, or had your doctor jump through hoops to prescribe a medication, you’ve likely run into a REMS program.

What Exactly Is a REMS Program?

REMS stands for Risk Evaluation and Mitigation Strategies. It’s a formal system created by the U.S. Food and Drug Administration in 2007 under the Food and Drug Administration Amendments Act (FDAAA). The goal isn’t to block access to dangerous drugs-it’s to make sure those drugs can still be used when needed, but with extra layers of protection.

Think of it this way: most drugs come with a label that lists side effects. That’s standard. REMS kicks in when the risk is so serious that the label alone isn’t enough. For example, isotretinoin (Accutane) can cause severe birth defects. Clozapine can wipe out your white blood cells. Thalidomide, once infamous for causing limb deformities in babies, is still used today to treat certain cancers and leprosy-but only under strict controls.

REMS doesn’t apply to every drug. In fact, it’s only used for about 5% of FDA-approved medications. But those 5% include some of the most critical treatments for cancer, severe mental illness, autoimmune diseases, and chronic pain. As of October 2023, there are 78 active REMS programs covering around 150 drugs. That’s more than double the number from 2015.

How Do REMS Programs Work?

REMS programs aren’t one-size-fits-all. Each one is built around the specific danger of the drug. The FDA requires three main types of elements:

  • Medication Guides: Printed handouts given to patients explaining the risks in plain language.
  • Communication Plans: Letters, emails, or training materials sent to doctors and pharmacists about how to safely use the drug.
  • Elements to Assure Safe Use (ETASU): The strictest layer. This might mean only certified doctors can prescribe, patients must be enrolled in a registry, or the drug can only be given in a hospital or clinic.

Take Zyprexa Relprevv, a long-acting shot for schizophrenia. Because it can cause sudden dizziness, confusion, or even coma within minutes after injection, it can only be given in certified clinics. Patients must be monitored for at least three hours after each dose. That’s not a suggestion-it’s the law.

Another example: the iPLEDGE program for isotretinoin. Before a pharmacy can fill the prescription, the patient must prove they’ve had two negative pregnancy tests, completed online counseling, and registered in the system. The doctor must also be certified. All of this adds up to delays-sometimes 3 to 7 days-before treatment starts.

Who Runs REMS Programs?

The FDA sets the rules, but the drug companies pay for and run the programs. That’s a key detail. When a company gets approval for a high-risk drug, they have to propose a REMS plan and prove they can handle it. The FDA reviews and approves it, but once it’s live, the company is responsible for training doctors, managing registries, tracking prescriptions, and reporting data.

This puts a huge burden on pharmaceutical companies. The industry spends about $1.2 billion a year just on REMS. For simpler programs-like just handing out patient guides-it might cost $500,000 a year. But for complex ones, like those requiring patient registries, special pharmacies, and lab monitoring, costs can hit $15 million annually.

And if they mess up? The FDA doesn’t hold back. In 2022, the agency issued 17 warning letters to drugmakers for failing to meet REMS requirements. One generic manufacturer paid a $2.1 million settlement for not properly managing the clozapine REMS program.

Doctor signing REMS forms while patient registration steps float in the air beside them.

Why Do REMS Programs Cause Delays?

There’s a reason patients and doctors complain. A 2019 study in JAMA Internal Medicine found that REMS drugs took an average of 5.4 days longer to be prescribed for the first time. For rare diseases, the delays were even worse.

Why? Because every step adds friction:

  • Doctors have to complete 1-2 hours of training, then register with the REMS system.
  • Pharmacists spend 15-20 minutes per REMS prescription verifying eligibility through separate online portals.
  • Only 35% of REMS systems connect directly to electronic health records. That means staff have to log in to multiple websites, enter data manually, and double-check everything.

A 2022 survey of 1,250 U.S. physicians found that 68% reported delays in starting REMS drugs. Forty-two percent said those delays hurt patient outcomes. Pharmacists aren’t spared either. Nearly three-quarters of hospital pharmacists said they spent 2-5 extra hours a week just on REMS paperwork.

On Reddit’s r/pharmacy forum, one user described the iPLEDGE system as a “nightmare.” Another said they had to call a patient’s dermatologist three times because the online system didn’t recognize the patient’s last name. These aren’t edge cases-they’re everyday realities.

Are REMS Programs Actually Making Patients Safer?

Supporters say yes. Dr. Robert Temple, former top FDA scientist, called REMS “essential” for bringing life-saving drugs to market that would otherwise be too risky. Without REMS, drugs like thalidomide or clozapine might never have been approved.

But critics point to evidence that some REMS programs don’t work as intended. Dr. Aaron Kesselheim from Harvard testified in 2021 that the REMS for extended-release opioids required doctors to take training-but didn’t require monitoring patients for addiction. He argued that the training didn’t reduce misuse, but still created delays.

The FDA admits this too. In 2022, former Acting Commissioner Dr. Janet Woodcock said, “Not all REMS programs have been equally effective.” The agency now requires drugmakers to prove their REMS isn’t creating unnecessary barriers, especially for patients in rural areas or those with rare diseases.

And there’s progress. In August 2023, the FDA allowed the first REMS program-thalidomide’s-to be discontinued after 20 years. Why? Because the risks became better understood, and safer alternatives were available. That’s a sign the system can evolve.

Futuristic control room displaying interconnected REMS drug programs with a rural access alert flashing.

What’s Changing in REMS Today?

The FDA is trying to fix the biggest problems: complexity and lack of data. Since 2023, they’ve launched the REMS Integration Initiative, which has standardized 22 out of 78 programs onto a single digital platform. That means fewer logins, less manual entry, and fewer errors.

They’re also testing digital tools. Pilot programs are now using smartphone apps to track patients on anticoagulants in real time. Instead of requiring monthly blood tests, patients might use an app to log symptoms or connect to a wearable device.

Looking ahead, Evaluate Pharma predicts that by 2027, 45% of new cancer drugs will need REMS-up from 38% in 2023. That’s because these drugs are more targeted, more powerful, and often come with unpredictable side effects.

But here’s the big gap: a 2023 FDA-PhRMA report found that 63% of REMS programs still don’t have clear metrics to prove they’re actually improving safety. Without data, it’s hard to know if the delays, costs, and headaches are worth it.

What This Means for Patients and Providers

If you’re prescribed a REMS drug, expect more steps. You might need to:

  • Complete online training or sign paperwork.
  • Get lab tests before and during treatment.
  • Visit a certified provider or pharmacy.
  • Wait longer than usual for your prescription.

Don’t assume it’s a mistake if your doctor says, “This one requires special approval.” It’s not about them-it’s about the law.

For providers, the challenge is managing the workflow. If your office still uses paper forms or manual checks, you’re falling behind. The future of REMS is digital, integrated, and automated. Those who adapt will save time-and keep patients on treatment.

For patients with rare diseases or those living far from specialty clinics, REMS can feel like a wall. Advocacy groups like NORD are pushing for better access: telehealth options, mobile clinics, and flexible monitoring. The FDA is listening-but change is slow.

REMS programs are not perfect. But they’re necessary. They allow us to use powerful drugs without repeating past tragedies. The real question isn’t whether REMS should exist-it’s how we can make them smarter, faster, and fairer.

What drugs require a REMS program?

REMS applies to prescription drugs with serious safety risks that can’t be managed through standard labeling alone. Examples include isotretinoin (for acne), clozapine (for schizophrenia), thalidomide (for cancer and leprosy), Zyprexa Relprevv (for schizophrenia), and certain opioid pain medications. As of 2023, 78 REMS programs cover about 150 drugs, mostly in oncology, neurology, and immunology.

Who is responsible for running a REMS program?

The pharmaceutical company that makes the drug is responsible for designing, funding, and managing the REMS program. The FDA approves the plan and monitors compliance, but the company handles everything from training doctors to maintaining patient registries and reporting data.

Can a REMS program be removed?

Yes. The FDA can remove or modify a REMS if new evidence shows the risks are better understood, safer alternatives exist, or the program isn’t improving safety. In August 2023, the FDA ended the REMS for thalidomide after 20 years, making it the first program to be fully discontinued.

Do REMS programs delay patient care?

Yes, often. Studies show REMS drugs take an average of 5.4 days longer to be prescribed. For patients with rare diseases or those in rural areas, delays can be even longer due to limited certified providers, paperwork, and system errors. Some patients stop treatment because of the frustration.

How is the FDA improving REMS?

The FDA is standardizing REMS platforms to reduce paperwork, integrating with electronic health records, and testing digital tools like smartphone apps for real-time monitoring. They now require drugmakers to prove their REMS doesn’t create unnecessary access barriers-especially for underserved populations.